RxDoctor Payments Data

Sandya Jiandani, MD

Family Medicine · Tallahassee, FLNPI 1841850229

Payments from drug & device makers

$1,593in general payments, 2019–2025

Across 75 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$328
  • AbbVie$231
  • Pfizer$199
  • Boehringer Ingelheim$198
  • Novo Nordisk$190
  • Lilly USA, LLC$114
  • plus $332 from 9 others

What the payments were for

  • Food & beverage$1,593100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,593 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$44,671
Medicare patients
90
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate89$85,404
TrulicityDulaglutide52$55,668
EliquisApixaban58$44,424
OzempicSemaglutide26$41,955
FarxigaDapagliflozin Propanediol32$34,267
JardianceEmpagliflozin18$25,530
MounjaroTirzepatide19$16,982
MyrbetriqMirabegron30$15,955
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$9,647
EntrestoSacubitril/Valsartan12$8,217
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,843
Breo ElliptaFluticasone/Vilanterol16$7,428
Atorvastatin Calcium252$3,905
Incruse ElliptaUmeclidinium Bromide12$3,625
Duloxetine Hcl90$2,832

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$33$85,40489 claims
Lilly USA, LLCTrulicity, Mounjaro$114$72,65071 claims
PfizerEliquis$199$44,42458 claims
AstraZenecaFarxiga, Breztri Aerosphere$328$42,11045 claims
Novo NordiskOzempic$190$41,95526 claims
Boehringer IngelheimJardiance$198$25,53018 claims
Astellas Pharma US IncMyrbetriq$25$15,95530 claims
NovartisEntresto$97$8,21712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →